文献速递MDS 与骨髓增殖性肿瘤白血病

PIM1在骨髓增殖性肿瘤中的致病与治疗意义

PIM1 in myeloproliferative neoplasms: potential pathogenic and therapeutic implications.
PubMed 文献 · Leukemia · 2026-09-28

骨髓增殖性肿瘤(MPN)中JAK2抑制剂无法清除恶性克隆或逆转骨髓纤维化,且存在耐药和不耐受。近期研究识别PIM1激酶为MPN发病的重要介质,其表达上调通过mTORC1、BAD、MYC、HIF-1α和TGF-β等下游效应器促进异常增殖和疾病进展。PIM1参与JAK2抑制剂持续细胞生长,抑制PIM1可恢复JAK2突变细胞对芦可替尼的敏感性;小鼠模型遗传消融或药理抑制PIM1可显著减轻骨髓纤维化表型。PIM抑制剂正在骨髓纤维化患者中开展临床试验。

要点

  • PIM1在MPN造血祖细胞中表达上调,促进异常增殖和疾病进展。
  • 抑制PIM1可恢复JAK2突变细胞对芦可替尼的敏感性。
  • PIM抑制剂正在骨髓纤维化患者中开展临床试验。

核心结论

  • PIM1是MPN发病的重要介质,靶向PIM1具有治疗潜力。

研究设计与样本

  • 综述,总结PIM1在MPN中的生物学、分子机制及靶向治疗转化潜力。

主要发现

  • PIM1表达在MPN造血祖细胞中上调,可能通过mTORC1、BAD、MYC、HIF-1α和TGF-β等下游效应器促进异常增殖和疾病进展。
  • PIM1参与JAK2抑制剂持续细胞生长,抑制PIM1可恢复JAK2突变细胞对芦可替尼的敏感性。
  • 小鼠模型遗传消融或药理抑制PIM1可显著减轻骨髓纤维化表型。

临床怎么用

  • PIM1抑制可能作为MPN尤其是骨髓纤维化的治疗策略,PIM抑制剂正在临床试验中评估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Myeloproliferative neoplasms (MPNs) are clonal hematologic malignancies characterized by the overproduction of mature myeloid lineage cells. Although JAK2 inhibitors, such as ruxolitinib, can alleviate constitutional symptoms, they typically fail to eradicate malignant clones or reverse bone marrow fibrosis. Moreover, treatment failure and drug intolerance often limit their long-term use. Recent studies have identified PIM1 kinase as an important mediator of MPN pathogenesis. PIM1 expression is upregulated in MPN hematopoietic progenitors, which may contribute to aberrant proliferation and disease progression by regulating key downstream effectors, including mTORC1, BAD, MYC, HIF-1α, and TGF-β. Notably, PIM1 contributes to JAK2 inhibitor-persistent cell growth, and its inhibition restores ruxolitinib sensitivity in JAK2 mutant cells. Preclinical studies using genetic ablation and pharmacological inhibition of PIM1 have shown significant attenuation of the myelofibrosis phenotype in mouse models, providing a strong rationale for targeting this kinase. PIM kinase inhibitors are currently being evaluated in clinical trials for patients with myelofibrosis. This review summarizes the current understanding of PIM1 biology in the context of MPNs, details the molecular mechanisms underlying its pathogenic contributions, and evaluates the translational potential of PIM1-targeted therapies for MPNs.

来源:Leukemia,查看原文。版权归原作者所有。

引用

  1. Dutta A, Varricchio L, Hoffman R, et al. PIM1 in myeloproliferative neoplasms: potential pathogenic and therapeutic implications. Leukemia. 2026. PMID: 42806053. doi:10.1038/s41375-026-03144-5

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。